NuCana is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by applying its ProTide technology to transform some of the prescribed chemotherapy agents, nucleoside analogs, into medicines. Utilizing its proprietary technology, Co. is developing new medicines, ProTides, designed to overcome main cancer resistance mechanisms and generate concentrations of anti-cancer metabolites in cancer cells. Co.'s ProTide candidates, Acelarin® and NUC-3373, are chemical entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil, respectively, two chemotherapy agents. Co. is evaluating NUC-7738 in clinical trial for patients with solid tumors.
|
Free NCNA Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (3.60 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: NCNA Stock Forecast Based on Zacks ABR data; powered by Xignite |